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Warfarin-related nephropathy in
patients with chronic kidney
disease
To the Editor: We read with great interest the entity
described by Brodsky et al.1 as warfarin-related nephropathy,
which occurs in patients with chronic kidney diseases treated
with anticoagulant doses of warfarin. In the 1970s and
early eighties, the combination therapy of cyclophosphamide,
dipyridamole, and warfarin, known as the Melbourne
Cocktail, was introduced and popularized by Professor
Priscilla Kincaid-Smith. KT Woo, on one of his sabbaticals
at the Royal Melbourne Hospital, was tasked by Kincaid-
Smith to analyze the results of patients with immunoglobulin
A nephritis treated with the above triple therapy in which
warfarin was given in anticoagulant doses to reduce
thrombotest values to between 7 and 15%. His analysis
had shown that patients on triple therapy had worsening
of renal function compared to the control group, in whom
renal function did not deteriorate as much. Also, in the
treatment group, there was more glomerular bleeding as
evidenced by urinary red blood cell counts compared with the
control group. However, proteinuria improved in the
treatment group though there was no improvement in
renal function. The data were subsequently published by
Walker et al.2
When we devised our own studies in Singapore,3 because
our Asian patients had a tendency to take traditional herbal
medicine, we had to be cautious with the use of warfarin.
Hence we employed an antithrombotic dose of warfarin to
keep thrombotest values no lower than 30% in the triple
regime. We did not notice the problem of hematuria in the
treatment group. In fact, the treatment group showed a
reduction of proteinuria and preservation of renal function
compared with the control group. We had postulated then
that anticoagulant doses of warfarin were deleterious and
could cause glomerular hemorrhage with renal deterioration.
Our earlier observation on warfarin therapy4 is in agreement
with Brodsky’s postulate that warfarin-related nephropathy is
simply a reﬂection of acute kidney injury due to warfarin-
induced glomerular hemorrhage when warfarin is prescribed
in anticoagulant doses.
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The Authors Reply:We are delighted to respond to the letter
by Dr Woo et al. entitled ‘Warfarin-related nephropathy in
patients with chronic kidney disease’.1 Dr Woo et al. will be
pleased to know that we became aware of their work and cited
it in our recent commentary.2 They may be even more pleased
by the case described below. It would be the ﬁrst report of the
condition predicted by Dr Woo et al. and ourselves.
This 48-year-old man had rheumatic fever with aortic
valve involvement since childhood. An aortic prosthetic valve
was placed in 2007 and warfarin therapy was begun. Mild
hematuria and proteinuria were detected prior to the surgery.
After the surgery, he experienced numerous episodes of gross
hematuria, especially when his international normalized ratio
(INR) was43.0. His serum creatinine slowly increased to the
2mg/dl range. Proteinuria was low (spot protein/creatinine
ratio 0.3). The urine sediment showed 450 red blood cells
(RBCs)/high-power ﬁeld (HPF) and many hemoglobin and
RBC casts. Acanthocytes were 1–3/HPF. Kidney biopsy showed
mild mesangial immunoglobulin A (IgA) deposits, moder-
ately advanced interstitial ﬁbrosis, and numerous RBCs in the
tubules. Evidence that this is mild IgA nephritis complicated
by recurrent warfarin-related nephropathy (WRN) is the
following: (1) the glomeruli show mild IgA deposits; (2) the
degree of glomerular obsolescence is small compared to the degree
of glomerular ﬁltration rate loss (16 vs. 50%) and proteinuria
is minimal; and (3) the interstitium is extensively ﬁbrosed.
Therefore, we suggest that the chronic kidney disease likely is
mainly the result of tubular injury from WRN. He may be at
especially strong risk for WRN because he requires warfarin
sufﬁcient to maintain his INR at 2.5–3.5.
The notion that glomerular disease can increase the risk of
WRN is supported by work describing WRN in patients with
both thick glomerular basement membrane (GBM) and thin
GBM, glomerulonephritis,3,4 and our epidemiology studies of
WRN.5
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